Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?.
- Author:
Dilek UNAL
1
;
Celalettin EROGLU
;
Arzu TASDEMIR
;
Hatice KARAMAN
;
Neslihan KURTUL
;
Arzu OGUZ
;
Sema Sezgin GOKSU
;
Bunyamin KAPLAN
Author Information
- Publication Type:Original Article
- Keywords: Kallikrein-11; Lung neoplasms; Survival
- MeSH: Biological Markers; Carcinoma, Non-Small-Cell Lung*; Chemoradiotherapy*; Disease-Free Survival; Humans*; Kallikreins*; Lung Neoplasms; Survival Rate
- From:Cancer Research and Treatment 2016;48(1):98-105
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Involvement of human kallikreins (hKs) in human cancers has been reported and several hKs are promising biomarkers of various cancers. The aim of this study was to evaluate the prognostic significance of hK11 expression in patients with non-metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The study included 44 patients with NSCLC. hK11 expression was determined by immunohistochemical staining. RESULTS: The estimation of disease-free and overall survival by Kaplan-Meier was 11 months and 17 months, respectively. The estimation of overall survival by Kaplan-Meier was significantly higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (20 months vs. 11 months, p=0.032). Although not statistically different, the estimation of disease-free survival by Kaplan-Meier was higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (12 months vs. 9 months, p=0.113). Multivariate Cox regression analysis showed that the overall survival rates were significantly associated with response to chemoradiotherapy and the degree of staining with hK11. CONCLUSION: The stronger hK11 expression in NSCLC appears to be associated with better survival rates. hK11 may be a prognostic biomarker of NSCLC.
